The Trump administration is preparing to introduce a sweeping new Medicare pilot program that could significantly reshape how care decisions are made for millions of Americans. The initiative has drawn widespread attention—and debate—because, for the first time in traditional Medicare (not just Medicare Advantage), patients will be required to obtain prior authorization before undergoing certain medical procedures.
Program Launch and States Involved
Set to begin in January 2026, the pilot program will initially operate across six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. According to the Centers for Medicare & Medicaid Services (CMS), the program’s stated goal is to reduce fraud, waste, and unnecessary spending in one of the government’s most expensive programs.
Given that Medicare accounts for nearly one-quarter of the federal budget, the initiative reflects former President Trump’s push to rein in costs by limiting what he views as excessive or unwarranted expenditures.
A New Approach to Medicare Oversight
What makes this program especially notable is its reliance on private contractors and artificial intelligence (AI) systems to review authorization requests. While CMS has assured the public that licensed clinicians will make final determinations, the initial screening process will be heavily influenced by AI and automated decision-making tools.
This shift has sparked concerns among healthcare professionals and patient advocates. Many of the affected procedures are commonly used to treat chronic conditions among older adults, raising fears that access to care could become more complicated and burdensome.
Procedures Requiring Prior Authorization
According to reporting by The New York Times journalist Teddy Rosenbluth, the following medical procedures will fall under the new prior authorization requirements beginning in 2026:
-
Electrical Nerve Stimulators
-
Sacral Nerve Stimulation for Urinary Incontinence
-
Phrenic Nerve Stimulator
-
Deep Brain Stimulation for Essential Tremor and Parkinson’s Disease
-
Vagus Nerve Stimulation
-
Induced Lesions of Nerve Tracts
-
Epidural Steroid Injections for Pain Management (excluding facet joint injections)
-
Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fractures (VCF)
-
Cervical Fusion
-
Arthroscopic Lavage and Arthroscopic Debridement for the Osteoarthritic Knee
-
Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
-
Incontinence Control Devices
-
Diagnosis and Treatment of Impotence
-
Percutaneous Image-Guided Lumbar Decompression for Spinal Stenosis
-
Skin and Tissue Substitutes (only in states with active Local Coverage Determinations)
What This Means for Medicare Beneficiaries
While CMS frames the program as a necessary step to improve efficiency and protect taxpayer dollars, critics argue it could delay care, create new bureaucratic hurdles, and place vulnerable seniors at risk of denied or postponed treatment.
As the 2026 launch date approaches, patients, providers, and policymakers alike will be closely watching how this controversial program unfolds—and whether it truly strikes the balance between cost savings and patient access to essential care.